BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Canyon Pharmaceuticals Honored with Frost & Sullivan Award for Product Differentiation Excellence in Parenteral Anticoagulants


10/18/2011 8:18:42 AM

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Frost & Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants recognizes Canyon Pharmaceuticals Group AG for the development and launch of Iprivask® (desirudin for injection). “Iprivask has been shown to prevent thrombosis significantly more effectively than the standard of care, with no increase in bleeding risk. A simplified fixed dose regimen and easy subcutaneous administration coupled with an attractive pharmacological profile make Iprivask ideally suited for the acute care setting, a space in need of safe, effective and user friendly therapies. Through careful product differentiation during development, Canyon Pharmaceuticals has succeeded in uniquely positioning Iprivask to be very competitive in an increasingly crowded market,” noted Frost & Sullivan Analyst Debbie Toscano.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES